Recursion Pharmaceuticals (NASDAQ:RXRX) Trading Down 10.9% After Insider Selling

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) dropped 10.9% during trading on Friday after an insider sold shares in the company. The stock traded as low as $3.38 and last traded at $3.3850. Approximately 9,626,800 shares were traded during mid-day trading, a decline of 44% from the average daily volume of 17,224,771 shares. The stock had previously closed at $3.80.

Specifically, Director Blake Borgeson sold 30,000 shares of the stock in a transaction on Tuesday, June 2nd. The stock was sold at an average price of $3.68, for a total value of $110,400.00. Following the transaction, the director directly owned 6,169,863 shares in the company, valued at approximately $22,705,095.84. This trade represents a 0.48% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Wall Street Analyst Weigh In

A number of research analysts have commented on RXRX shares. Bank of America decreased their price objective on Recursion Pharmaceuticals from $7.00 to $6.00 and set a “neutral” rating on the stock in a research report on Wednesday, February 25th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Recursion Pharmaceuticals in a research report on Tuesday, April 21st. JPMorgan Chase & Co. decreased their price objective on Recursion Pharmaceuticals from $11.00 to $10.00 and set an “overweight” rating on the stock in a research report on Thursday, April 30th. Morgan Stanley increased their price objective on Recursion Pharmaceuticals from $5.00 to $5.50 and gave the company an “equal weight” rating in a research report on Thursday, May 14th. Finally, Wall Street Zen lowered shares of Recursion Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, March 28th. Two research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $8.10.

Recursion Pharmaceuticals Price Performance

The company has a debt-to-equity ratio of 0.01, a quick ratio of 5.47 and a current ratio of 5.47. The firm has a market capitalization of $1.79 billion, a P/E ratio of -2.81 and a beta of 1.04. The company has a 50-day moving average price of $3.30 and a 200-day moving average price of $3.82.

Recursion Pharmaceuticals (NASDAQ:RXRX) last posted its quarterly earnings results on Wednesday, May 6th. The company reported ($0.22) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.30) by $0.08. Recursion Pharmaceuticals had a negative return on equity of 54.33% and a negative net margin of 842.95%.The business had revenue of $6.47 million for the quarter, compared to analyst estimates of $15.78 million. During the same period last year, the company earned ($0.50) EPS. The firm’s revenue was down 56.8% on a year-over-year basis. On average, sell-side analysts predict that Recursion Pharmaceuticals, Inc. will post -1.02 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of RXRX. Vanguard Group Inc. grew its holdings in Recursion Pharmaceuticals by 18.6% during the fourth quarter. Vanguard Group Inc. now owns 47,187,759 shares of the company’s stock valued at $192,998,000 after purchasing an additional 7,407,606 shares during the period. ARK Investment Management LLC grew its holdings in Recursion Pharmaceuticals by 11.2% during the fourth quarter. ARK Investment Management LLC now owns 37,316,856 shares of the company’s stock valued at $152,626,000 after purchasing an additional 3,771,357 shares during the period. State Street Corp grew its holdings in Recursion Pharmaceuticals by 38.7% during the fourth quarter. State Street Corp now owns 25,333,888 shares of the company’s stock valued at $103,616,000 after purchasing an additional 7,064,963 shares during the period. Geode Capital Management LLC grew its holdings in Recursion Pharmaceuticals by 13.6% during the fourth quarter. Geode Capital Management LLC now owns 10,934,252 shares of the company’s stock valued at $44,731,000 after purchasing an additional 1,310,695 shares during the period. Finally, Norges Bank acquired a new position in Recursion Pharmaceuticals during the fourth quarter valued at approximately $23,473,000. Institutional investors own 89.06% of the company’s stock.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc (NASDAQ: RXRX) is a biopharmaceutical company that combines advanced automation, artificial intelligence and high-throughput biology to discover and develop novel therapeutics. The company’s proprietary platform integrates deep-learning algorithms with large-scale cellular imaging and chemical biology, enabling the rapid identification of potential drug candidates across a range of indications. By automating complex laboratory workflows and leveraging computational models, Recursion aims to accelerate the drug discovery process and expand the scope of targets that can be addressed.

At the core of Recursion’s offering is its digital biology platform, which captures billions of cell images under varying chemical and genetic perturbations.